和铂医药-B(02142):全人源超长效靶向TSLP抗体HBM9378/WIN378治疗COPD的II期 SIRIUS研究已完成首批患者给药

智通财经网
Jun 09

智通财经APP讯,和铂医药-B(02142)发布公告,公司的合作伙伴Windward Bio AG(Windward Bio)已在HBM9378/WIN378(亦称SKB378,一款全人源超长效靶向胸腺基质淋巴细胞生成素(TSLP)抗体)治疗慢性阻塞性肺疾病(COPD)的II期 SIRIUS研究中完成首批患者给药。

SIRIUS是一项全球II期随机、双盲、安慰剂对照、剂量探索研究,旨在评估HBM9378/WIN378在中重度COPD患者中的安全性、耐受性、药代动力学和药效学特征。

HBM9378/WIN378目前亦正于Windward Bio的II/III期POLARIS哮喘研究中进行评估,预计将于2026年下半年取得初步II期数据。Windward Bio预计HBM9378/ WIN378的首个哮喘III期研究将于2026年第四季度开始。SIRIUS COPD研究的启动将HBM9378/WIN378的临床开发扩展至作为第二种主要呼吸系统疾病的COPD。

董事会认为,SIRIUS COPD研究的启动标志着HBM9378/WIN378持续取得临床进展,并进一步佐证了该分子作为治疗免疫性疾病的差异化、超长效靶向TSLP抗体的潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10